Domo Health and Roche Pharma Suisse SA are teaming up for a clinical study that aims to develop a ‘digital health solution detecting hypoventilation and warning signs of respiratory infections’.
The study is aimed specifically at patients who suffer from spinal muscular atrophy (SMA), a rare neuromuscular disease which often forces them to use a wheelchair. The unique method presented by Domo Health and Roche Pharma aims to improve the quality of life of patients suffering from spinal muscular atrophy, by ‘providing a reliable solution for more independence and safety, both at home and when on the move’.
The proposed method combines a home alert system, clinical expertise and real-time health data to detect the first signs of illness and immediately alerts the doctors, caregivers and emergency centres. The aim is to provide care as soon as possible and save lives in emergency situations.
Domo Health has already designed its own AI-driven algorithms by analyzing billions of physiological and behavioral data points to detect and predict sudden deteriorations in illness. Roche is already recruiting the first patients for the study with an aim to develop digital biomarkers to predict respiratory failure and save lives.
The results of the study are expected for the second quarter of 2023.
